Press

2022-05-23

Kancera provides operational update in connection with the interim report for the first quarter of 2022

This is a translation of a press release published in Swedish by Kancera AB (publ) on May 20, 2022.

Read More
2022-05-20

Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851

First quarter in brief January – MarchFinancial summary for the first quarter and the period January – March 2022·        Net sales amounted to SEK 0 million (SEK 0.0 million).·        R&D costs amounted to SEK 10,6 million (8,2 million).·        Operating...

Read More
2021-11-22

Kancera’s drug candidate KAND145 effectively reduces tumor size in a preclinical model of ovarian cancer

This is a translation of press release in Swedish (2021-11-22). Kancera AB (Nasdaq First North Premier Growth Market: KAN) today presents preclinical results that show that KAND145 effectively reduces tumor size in a disease model of ovarian cancer. These...

Read More
2021-11-19

Kancera reports top-line data from the phase IIa study with KAND567 in COVID-19 patients

This is a translation of a press release in Swedish published 2021-11-18. Kancera AB (Nasdaq First North Premier Growth Market: KAN) presents results from the exploratory phase IIa study with KAND567 in patients with COVID-19. The randomized double-blinded study...

Read More
2021-06-16

Kancera has completed patient recruitment for the COVID-19 study with KAND567

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the recruitment of patients for the exploratory phase IIa study with KAND567 has ended after just over 80 percent of the originally planned number of COVID-19 patients have...

Read More
2021-05-24

Kancera announces that an application for a clinical phase IIa study with KAND567 after heart attack has been submitted to the UK Medicines Agency (MHRA)

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the application for permission to start a phase IIa study evaluating the safety and cardioprotective effect of KAND567 in heart attack patients has been submitted to the...

Read More
2021-05-21

Interim report for first quarter 2021, 1 January – 31 March 2021

First quarter in brief Net sales for the period (January to March) amounted to SEK 0 million (SEK 0 million). R&D costs for the period amounted to SEK 8,2 million (SEK 9,7 million). Operating profit for the period amounted...

Read More
2021-01-15
2021-01-15

Kancera appoints a Scientific Advisory Board with leading scientists in cardiology and immunology

This is a translation of a press release in Swedish published December 21, 2020

Read More
2020-12-02

Agreement on development of HDAC6 inhibitors discontinued.

Kancera AB announces today that the pharmaceutical company Grünenthal GmbH has chosen to terminate the parties' research and option agreement. Since the end of 2018, Grünenthal has been responsible for the development of Kancera's series of HDAC6 inhibitors and...

Read More